ASCO 2020 virtual annual meeting – day 2

Our live coverage from this year’s slimmed down, virtual version of the American Society of Clinical Oncology (ASCO) annual meeting continues at 8am (ET) as we move into day 2 of the oncology event.

Today ASCO 2020 kicks off in earnest with the Presidential address, followed by highlights in breast, head and neck, and gastrointestinal cancers.

It follows our live coverage of ASCO 2020 day 1, which looked at Amgen’s next-generation proteasome inhibitor Kyprolis, patient-reported outcome measures (PROMs), the impact of COVID-19 on thoracic cancers, post-surgery lung cancer data for AstraZeneca’s Tagrisso and much more.

ASCO-2020-Day2

View the live coverage from day two ASCO 2020 below (please allow the blog a few moments to load), and we will also have live ASCO 2020 coverage on Sunday 31 May from 8am (ET):

 

Syneos Health ASCO 2020

Syneos Health® (Nasdaq:SYNH) is the only fully integrated biopharmaceutical solutions organisation. The Company, including a Contract Research Organisation (CRO) and Contract Commercial Organisation (CCO), is purpose-built to accelerate customer performance to address modern market realities. We bring together approximately 24,000 clinical and commercial minds, including 4,400 experts dedicated to oncology and haematology who collaborate with our customers to change the history of cancer treatments.  We embrace our customers’ boldest visions and bring experience, innovation and our passion to every oncology program we run.  Learn more at: https://www.syneoshealth.com/collaborate-for-a-cure.